Neuroscience, practical frameworks and what actually works — for founders, high-achievers and anyone navigating the post-retreat process.
The complete framework for understanding the integration gap — why the psychedelic experience alone doesn't produce lasting change, and what the neuroscience says about closing it.
Day-by-day grounding practices, the BDNF neuroplasticity window, common mistakes, and how to know when you need professional support.
What makes a psychedelic experience "difficult," why these are often the most valuable, and the specific processing framework that works.
Peer-reviewed evidence (Lemercier & Terhune, 2018) for why hypnotic and psychedelic states share neural mechanisms — and how to use this for integration.
The integration gap hits hardest in founders and entrepreneurs. Specific patterns, why cognitive skills don't help, and what actually works.
Only 18% of people with post-psychedelic difficulties seek professional support. How to find, vet, and choose the right integration therapist — including the red flags.
74% of ketamine patients relapse within 30 days without integration. How to use the BDNF neuroplasticity window after infusions to make the effects stick.
54% of variance in depression reduction after psilocybin is explained by the quality of ego dissolution. Why integrating it is fundamentally different from processing a regular psychedelic experience.
50% of entrepreneurs have anxiety — 2.6× the general population. An honest look at what psilocybin, LSD, MDMA, and ketamine trials show about anxiety outcomes, and why integration determines whether benefits last.
67% PTSD remission in MAPP1, 71.2% in MAPP2 — but the FDA rejected psilocybin-assisted therapy in 2024. What the trials show, what they don't, and why the fear extinction window requires structured integration to hold.
Not all difficult post-psychedelic states are crises. 84.5% of people find their challenging experiences ultimately valuable. How to distinguish a dark night from clinical crisis — and what the process asks of you.
r=−0.85 between therapeutic alliance and adverse events. The ReSPCT Delphi 2025 on environmental standards. Why Leary's phrase became the most empirically validated concept in psychedelic medicine.
Psilocybin binds TrkB with 1000× higher affinity than classic antidepressants. The COMPASS Phase 3 results, the NEJM 2021 head-to-head vs escitalopram, and what the remission rates mean for treatment-resistant cases.
John Welwood coined the term in 1984. High-achievers are disproportionately vulnerable after psychedelics — the same cognitive agility that drives success becomes the primary defense against actual integration work.
The BDNF neuroplasticity window closes at 2–4 weeks. Most integration work happens after that. A week-by-week breakdown of what the nervous system is doing and where structured support matters most.
82% of naturalistic psychedelic users report major life changes across key life domains. A practitioner's guide to integrating identity shifts, career changes, and values divergence after a retreat.
Stanford's ibogaine study: 88% PTSD reduction. Neuroplasticity window: 90 days. What structured integration actually requires — especially for executives and founders doing ibogaine outside addiction recovery.
Somatic psychedelic integration reaches where talk therapy can't. 15 of 16 studies confirmed body-based work is neurobiologically necessary. How to work with body-stored material after a retreat.
Taking a psychedelic alone was indirectly associated with ending a relationship (n=798). A guide to integrating relational shifts, navigating partner divergence, and protecting partnerships after a retreat.
The 72-hour pre-session protocol most guides miss. BDNF priming, intention crystallization, somatic baseline, and why executive clients need more preparation than standard ketamine prep covers.
MAPP2: 71.2% loss of PTSD diagnosis (Nature Medicine, 2023). Complex PTSD vs PTSD, the 6-hour fear extinction window, post-CRL access pathways, and why standard frameworks miss founder integration.
ReSPCT 2025 Delphi consensus on preparation standards. Why intention setting fails when done from prefrontal-only state, and the implicit memory priming protocol for the 30 days before a session.
Where is psychedelic therapy actually legal in 2026? Oregon, Colorado, New Mexico, Australia, Switzerland compared. 7 jurisdictions matrix with cost, wait time, travel, and documentation requirements.
SSRIs and psychedelics interact differently by substance: psilocybin and MDMA blunted, ketamine unaffected. Erritzoe 2024 shows 47% effect reduction. Taper math and reinstatement protocols.
Burnout ≠ depression. WHO ICD-11: exhaustion, cynicism, reduced efficacy. HPA-axis dysregulation, DMN hyperconnectivity, BDNF window. What psilocybin, MDMA, ketamine actually reset.
A practitioner-vetted framework. 12 red flags, 15 screening questions, ReSPCT 2025 standards. Based on 200+ post-retreat cases — patterns SERP doesn't cover.
10M Americans tried it in 2025. But Szigeti 2021 self-blinding RCT showed near-zero objective difference vs placebo. Why subjective gains are real and what executive context changes.
30-40% of OCD patients don't respond to SSRIs + ERP. Moreno 2006 pilot, Yale 2024 trial. How 5-HT2A disrupts the CSTC loop and why founder OCD presents differently.
Bogenschutz 2022 JAMA Psychiatry: 83% reduction in heavy drinking days vs 51% placebo (n=95). Why the founder/high-functioning case is missed by standard AUD frameworks.
Both suppress the default mode network. Smigielski 2019: 27% larger ego dissolution effects when combined. When meditation is integration and when it's bypass.
Mueller & Oppenheimer 2014: handwriting > typing for retention. 30 prompts mapped to BDNF window. Why journaling works as implicit-to-explicit memory bridge.
Haijen 2024 JAMA Psychiatry MIND ADHD LSD trial: modest improvement vs placebo. Hutten survey: 78% subjective gain in microdosers. Why ADHD founders self-medicate this way.
15-20 min non-narrative experience. Davis 2018: 79% lasting benefit, 33% report challenges >1 year. Why standard integration frameworks fail Bufo and what works.
Sewell 2006: ~50% remission/significant reduction in cluster sufferers. Schindler 2021 pulse-dosing RCT. Mechanism: serotonergic modulation of trigeminal pain pathways.
Direct comparison from a practitioner with Ecuador + Mexico retreat experience and 200+ post-retreat clients. Duration, character, evidence, legal — 9-row matrix.
Holze 2022 dose-equivalence: LSD 100μg ≈ psilocybin 20mg. But experience character, duration, and clinical applications differ. 8-row comparison table.
Bipolar II misdiagnosed for 8-12 years (Hirschfeld). Mania induction risk 4-9% after psilocybin. MDQ-style screening checklist and Aaronson 2024 JAMA Psych trial.
Nayak 2021: 47% of lithium + psychedelic combinations resulted in seizure or severe reaction (n=62). Mechanism, taper math, MDMA/ketamine differences.
Real path map: 6-12 year journey across 4 phases. CIIS, MAPS, Fluence, IPI, Naropa, Oregon facilitator compared. Cost, duration, prereq for each program.
VETS 93.2%, Stanford 88% PTSD remission, MAPP2 71.2%. Trump April 2026 EO + VA 9-site psilocybin trial. 4-substance comparison.
20% US adults have chronic pain. Castellanos 2020 review + Frontiers 2025 fibromyalgia pilot. Central sensitization, 5-HT2A, DMN suppression.
Rootman 2022 (n=8,703) shows subjective improvements vs Szigeti 2021 (n=191) shows zero objective effect. Microdose vs full-dose vs SSRI compared.
Peck 2023 Nature Medicine Phase 1 anorexia trial. DMN disruption + body-image flexibility. 30M Americans with ED, 5.6% anorexia mortality.
Ross 2016 + Griffiths 2016: 60-80% sustained reduction in cancer anxiety/depression. Agin-Liebes 2020: 4.5-year follow-up effects sustained.
LSD therapy requires longer preparation than psilocybin: 8-12h session, stricter SSRI washout, different mid-session intention strategy. Gasser 2014 baseline.
KAP $3-9K, Oregon $3-5K, Australia AUD 20-30K, retreats $3-15K. Hidden costs, ROI comparison vs SSRIs and coaching. Decision-stage guide for founders.
5-HT2B activation raises cardiac valve concerns. Sessions add 10-20 mmHg systolic + 20-30 BPM. Critical screening guide for 40+ executives.
DSM-5 292.89 explained. Halpern 2003: 4.2% prevalence in heavy users. Type I vs Type II distinction, treatment options, anxiety-amplification loop.
70% of founders feel "everything must change" in month 1, only 12% by month 6. 4-path framework: Pause / Sell / Reinvent / Pivot. 90-day decision freeze rule.
0.1-1% of users with vulnerability factors. Warning signs, risk factors, founder mode confusion. Studerus 2011 + DSM-5 + Krebs 2013 n=130,152.
9 patterns from 900+ integration sessions. Insight-only, no decision freeze, bypass mimicry, oversharing, mismatched practitioner.
4 routes compared: bioavailability (100% IV vs 30% troches), cost, FDA status. Wilkinson 2021 + Daly 2019 Spravato Phase 3.
Roseman 2018: mystical experience intensity r=0.6. Aday 2021 personality. 60-70% respond to standard protocol; 30-40% don't. Why.
Anderson 2020: 20-week sustained reduction in AIDS long-term survivors with prolonged grief. ICD-11 6B42 criteria. Founder grief patterns.
Before or after Series A? 90-180 day post-close window. Decision freeze rule. 18% considered exit/sell in 90 days, only 4% acted.
5 scripts: pre-retreat, day-after, 30-day check-in, "I'm changing", boundary. 60% of post-retreat strain comes from oversharing too early.
Estrogen upregulates 5-HT2A density (Sumner 1995). Cycle phase × response, contraceptives, perimenopause, pregnancy exclusion. Bremler 2023.
Comprehensive contraindications guide. Bipolar, SSRIs, lithium, cardiac, pregnancy, active suicidality. Mitchell 2021 MAPS exclusion criteria.
HFD hits 2-3% of adults (NIMH) but clinicians miss it. Why psilocybin trials show 57% remission. Pleasure-deficit + exhaustion + identity-fused performance.
5-phase structure inside 90 min: body scan, material assessment, direct work, behavioral protocol, closing. 72% underestimate what integration actually is.
Wealth event = mental health event. 4 transition types: successful exit, succession, forced exit, retirement. Standard exec coaching misses the foundation.
67% of psilocybin participants report 5+ nights of disrupted sleep. REM rebound, BDNF plasticity, circadian shift, and a 14-day recovery protocol.
The DMN is why your strategic mind won't shut off, and why psilocybin disrupts it (47% drop). Neuroscience for high-performers integrating insights.
31% of ayahuasca retreatants made a major life decision within 90 days. Cognitive flexibility, openness shift, and the 90-day deferral rule.
Psilocybin lifts mPFC glutamate 9.5%. AMPA blockade kills 80% of antidepressant effect. The plasticity window and what integration must protect.
Day-by-day breakdown of the 14-day window. ECN connectivity at week 1, BDNF elevation, and the founder protocol that captures it.
Acute impairment, longitudinal flexibility. 2025 meta-analysis and n=2,503 cohort data on attention and cognitive flexibility post-session.
Why MEQ-30 scores predict long-term outcomes across depression, AUD, and smoking cessation. What founders should measure post-session.
Heart rate, blood pressure, ECG, 5-HT2B valvulopathy risk. The full pre-retreat cardiovascular workup for high-performers.
Coaches cannot diagnose. Therapists cannot provide substances. The ethical scope of each role for 2026 founders choosing a provider.
Insomnia is the forgotten side effect. 4-week recovery pattern, MAPP1/MAPP2 adverse event data, and the executive sleep protocol.
Three Leiden trials, n=171 mega-analysis. Truth about microdosing for creativity, divergent thinking quality vs quantity.
Aerobic exercise, dietary inputs, sleep architecture during the 14-day BDNF window. The behavioral protocol that consolidates neuroplasticity.
Roseman 2019 EBI: emotional breakthrough predicts well-being better than mystical experience for many founders. Mechanism and integration.
MacLean 2011: openness change >1 year, larger than decades of life experience. What this means for founders integrating psilocybin.
Barrett 2020 NeuroImage: psilocybin alters claustrum-DMN connectivity. The densest 5-HT2A region as the missing neuroscience layer.
Johnson 2014: 80% abstinence at 6 months, 67% at 12+ months vs <35% standard. Mechanism, integration, founder context.
Kettner 2019: psychedelic-induced nature connectedness persists 24 months. Why founders rethink career after retreats.
Soler 2018: 4 ayahuasca sessions matched 8-week MBSR on acceptance. Decentering as core mechanism behind durable change.
Integration circles fill the gap when 1:1 therapy is unavailable. Bathje 2022 evidence, ethical concerns, founder fit.
Murphy 2022: alliance predicted depression outcome stronger than dose or mystical experience. What founders should look for in a guide.
DMT phase 2 trials show 10.8-point MADRS drop in 1 week. Why short-acting DMT integration differs from ayahuasca.
Yale Shao 2021: 10% dendritic spine growth from single psilocybin dose, persisting 1 month. What it means for integration timing.
Keltner and Yaden: awe predicts decreased narcissism 5 years post-psychedelic. Why high-achievers under-experience awe.
Neff: self-compassion strongest predictor of psychological flourishing post-trauma. Why insights collapse without it.
Stauffer 2021: avoidant attachment predicts challenging experiences; anxious predicts mystical. Why founders skew avoidant.
Agin-Liebes 2020: 60-80% sustained anxiolytic effect at 4.5 years after one psilocybin session. Founder fit.
Psilocybin reduces rumination via DMN modulation. Why perfectionist founders rebound within 60 days without somatic work.
Psychedelics open a memory reconsolidation window where implicit trauma can update. MDMA mechanism and integration protocol.
10 million US adults microdosed in 2025. Controlled trials tell a different story than the headlines. An honest synthesis of the evidence — and why integration still matters even at sub-perceptual doses.